FINANCE/FUNDING ARTICLES

  • Recurring Mistakes (And Remedies) For Life Sciences M&As
    Recurring Mistakes (And Remedies) For Life Sciences M&As

    Two members of a specialized life sciences investment banking group provide a list of avoidable missteps in M&A transactions and their respective remedies.

  • Not a Bad Year, After All
    Not a Bad Year, After All

    Peter Meath, who heads the Life Science Group at J.P. Morgan’s Commercial Banking business, offers advice to novice entrepreneurs for turning a company’s novel science into a viable business.

  • Investors Drumming Up New Solutions To The Industry’s Real Estate Crunch
    Investors Drumming Up New Solutions To The Industry’s Real Estate Crunch

    Investors are recognizing life sciences real estate as a valuable specialty asset class. In fact, it’s a trend gaining momentum as major real estate investment trusts (REITs) and entrepreneurial investors alike create new homes for life sciences activities.

  • Diversification Relieves Funding Pressure For Small Pharma
    Diversification Relieves Funding Pressure For Small Pharma

    Chronic pressure is a way of life for those starting pharmaceutical companies. It’s a life filled with rounds of funding, investor demands, performance deadlines, and possible compound failures. But what if the technology owned by a startup drug discovery company was suddenly in demand by some of the world’s largest food and beverage corporations? What if that opportunity gives you the flexibility and time to conduct your research on your own timetable?

  • Lessons In Collaborating With Big Pharma
    Lessons In Collaborating With Big Pharma

    Any small biopharma knows the importance of collaborating or partnering with larger companies and academic institutions. But where do you start, and who should be involved? And what kind of risk should you take on?

  • Government Funding And Technology: The Right Ticket For Small Pharma
    Government Funding And Technology: The Right Ticket For Small Pharma

    Soligenix is a late-stage biopharmaceutical company focused on rare diseases. The company’s president and CEO discusses how government grants and contracts can be one way to help fund research.

  • New Hampshire: A Biotech Microhub
    New Hampshire: A Biotech Microhub

    As the biotech sector in the U.S. continues to grow, it is doing so not just in hubs, but in smaller places like New Hampshire — where some of the state’s biopharma entrepreneurs say: “Smaller is better.”

  • How A Biotech Startup Networked Through The Valley Of Death
    How A Biotech Startup Networked Through The Valley Of Death

    We also sold our antibody drug candidate to Novartis in 2014 for another $5 million. We did everything we could to survive.

  • The Case For A Healthcare Futures Market
    The Case For A Healthcare Futures Market

    Now is the time to develop a novel financial instrument which will provide risk transfer, transparency, and more certainty. A futures market in healthcare is a product whose time has come.

  • Prospects For Healthcare Capital Markets In 2017
    Prospects For Healthcare Capital Markets In 2017

    As life sciences asset managers, our evaluation of the life science capital markets for the second quarter of 2017 is one of confidence, mediated by prudent caution. Our view has been based on a confluence of subjective and objective factors.

More finance/funding articles